SCHEMBL3582234

SCHEMBL3582234

CCOC(=O)c1cccnc1-c1ccc(OC(C)Cc2ccccc2)c(C#N)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.44
ALDH1A1 P00352 6/20 0.44
TDP1 Q9NUW8 4/20 0.44
L3MBTL1 Q9Y468 4/20 0.44
HSD17B10 Q99714 1/20 0.44
NPSR1 Q6W5P4 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTT P42858 2/20 0.43
GPR55 Q9Y2T6 1/20 0.43
S1PR1 P21453 2/20 0.43
XDH P47989 6/20 0.43
LMNA P02545 2/20 0.42
HPGD P15428 2/20 0.42
S1PR3 Q99500 1/20 0.42
S1PR5 Q9H228 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3590295 0.93 XDH (0.41) KDM4EALDH1A1TDP1L3MBTL1HSD17B10
SCHEMBL3579916 0.92 KDM4E (0.44) KDM4EALDH1A1TDP1L3MBTL1HSD17B10
SCHEMBL3593142 0.89 XDH (0.48) XDH
SCHEMBL3590470 0.85 KDM4E (0.44) KDM4EALDH1A1TDP1L3MBTL1HSD17B10
SCHEMBL3583167 0.85 XDH (0.53) XDH
SCHEMBL3589210 0.84 KDM4E (0.52) KDM4EALDH1A1TDP1L3MBTL1HSD17B10
SCHEMBL3587391 0.83 XDH (0.47) XDH
SCHEMBL3588218 0.83 XDH (0.45) KDM4EALDH1A1TDP1L3MBTL1CYP3A4
SCHEMBL3584935 0.82 KDM4E (0.48) KDM4EALDH1A1TDP1L3MBTL1NPSR1
SCHEMBL3590048 0.82 XDH (0.53) KDM4EALDH1A1TDP1L3MBTL1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004459-A1 2-PHENYLNICOTINIC ACID DERIVATIVE NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2010-01-07 US disclosed
EP-2128136-A1 2-PHENYLNICOTINIC ACID DERIVATIVE Nippon Zoki Pharmaceutical Co., Ltd. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004459-A1 2-PHENYLNICOTINIC ACID DERIVATIVE XDH, NUDT1, PNPO KDM4E 2392/4885ALDH1A1 429/4885TDP1 393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.